- Home
- AOMR vs ABEO Comparison
AOMR vs ABEO Comparison
Compare AOMR & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- ABEO
- Stock Information
- Founded
- AOMR 2018
- ABEO N/A
- Country
- AOMR United States
- ABEO United States
- Employees
- AOMR N/A
- ABEO N/A
- Industry
- AOMR Real Estate Investment Trusts
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- ABEO Health Care
- Exchange
- AOMR Nasdaq
- ABEO Nasdaq
- Market Cap
- AOMR 228.8M
- ABEO 237.4M
- IPO Year
- AOMR 2021
- ABEO 1980
- Fundamental
- Price
- AOMR $9.57
- ABEO $4.76
- Analyst Decision
- AOMR Buy
- ABEO Strong Buy
- Analyst Count
- AOMR 5
- ABEO 5
- Target Price
- AOMR $11.90
- ABEO $17.00
- AVG Volume (30 Days)
- AOMR 113.7K
- ABEO 470.7K
- Earning Date
- AOMR 03-04-2025
- ABEO 03-20-2025
- Dividend Yield
- AOMR 13.39%
- ABEO N/A
- EPS Growth
- AOMR N/A
- ABEO N/A
- EPS
- AOMR 1.17
- ABEO N/A
- Revenue
- AOMR $51,458,000.00
- ABEO N/A
- Revenue This Year
- AOMR N/A
- ABEO N/A
- Revenue Next Year
- AOMR $3.50
- ABEO $561.86
- P/E Ratio
- AOMR $8.17
- ABEO N/A
- Revenue Growth
- AOMR N/A
- ABEO N/A
- 52 Week Low
- AOMR $8.88
- ABEO $3.05
- 52 Week High
- AOMR $13.32
- ABEO $8.45
- Technical
- Relative Strength Index (RSI)
- AOMR 41.40
- ABEO 32.91
- Support Level
- AOMR $9.56
- ABEO $4.95
- Resistance Level
- AOMR $9.73
- ABEO $5.14
- Average True Range (ATR)
- AOMR 0.15
- ABEO 0.24
- MACD
- AOMR 0.00
- ABEO -0.03
- Stochastic Oscillator
- AOMR 22.03
- ABEO 8.70
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation, across interest rates and credit cycles.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.